Attached files

file filename
EX-99.2 - EX-99.2 - Tilray, Inc.d105344dex992.htm
EX-23.1 - EX-23.1 - Tilray, Inc.d105344dex231.htm
8-K - 8-K - Tilray, Inc.d105344d8k.htm

Exhibit 99.1

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS OF TILRAY

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

On December 15, 2020, Tilray, Inc. (“Tilray”) and Aphria Inc. (“Aphria”), entered into an Arrangement Agreement, under which the businesses of the two companies will be combined pursuant to a Plan of Arrangement (the “merger transaction”).

The following unaudited pro forma condensed combined financial statements (the “pro forma financial statements”) are based on the historical consolidated financial statements of Tilray and Aphria, as adjusted to give effect to the merger transaction. The unaudited pro forma condensed combined balance sheet as at December 31, 2020 (the “pro forma balance sheet”) gives effect to the merger transaction as if it had occurred on December 31, 2020. The unaudited pro forma condensed combined statement of net loss for the year ended December 31, 2020 (the “pro forma statement of net loss”) gives effect to the merger transaction as if it had occurred on January 1, 2020.

The transaction accounting adjustments consist of those necessary to account for the merger transaction as a reverse acquisition in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).

The pro forma financial statements do not necessarily reflect what the combined company’s financial condition or results of operations would have been had the merger transaction occurred on the dates indicated. They also may not be useful in predicting the future financial condition and results of operations of the combined company. The actual financial condition and results of operations of the combined company may differ significantly from the pro forma amounts reflected herein due to a variety of factors.

 

1


Unaudited Pro Forma Condensed Combined Balance Sheet

December 31, 2020

(in ‘000 of United States dollars)

 

     Aphria adjusted
historical
November 30, 2020
(note 6)
    Tilray
historical
December 31, 2020
    Transaction
accounting
adjustments
    Notes
(note 4)
     Pro forma
combined
December 31,
2020
 

Assets

           

Current assets

           

Cash and cash equivalents

   $ 144,713     $ 189,702     $ 37,426       H      $ 371,841  

Accounts receivable, net

     74,034       29,033       —            103,067  

Inventory

     174,817       93,645       27,355       C        295,817  

Prepayments and other current assets

     56,375       34,640       —            91,015  

Total current assets

     449,939       347,020       64,781          861,740  

Property and equipment, net

     499,164       199,559       1,490       D,E        700,213  

Operating lease, right-of-use assets

     5,393       17,985       274       E        23,652  

Intangible assets, net

     528,397       186,445       876,555       F        1,591,397  

Goodwill

     578,161       166,915       2,422,696       G        3,167,772  

Equity method investments

     —         9,300       —            9,300  

Other investments

     16,792       14,369       —            31,161  

Other assets

     2,309       4,356       —            6,665  

Total assets

   $ 2,080,155     $ 945,949     $ 3,365,796        $ 6,391,900  

Liabilities

           

Current liabilities

           

Bank indebtedness

     3,934       —         —            3,934  

Accounts payable

     62,667       17,776       —            80,443  

Accrued expenses and other

     117,501       39,946       33,841       K        198,111  

current liabilities

         6,823       L     

Income taxes payable

     12,760       —         —            12,760  

Accrued lease obligations

     1,360       2,913       —            4,273  

Warrant liability

     —         120,647       175,385       H        296,032  

Current portion of long-term debt

     11,708       —         —            11,708  

Total current liabilities

     209,930       181,282       216,049          607,261  

Accrued lease obligations

     34,560       30,623       —            65,183  

Deferred tax liability

     23,347       49,274       202,603       M        287,071  
         11,847       M     

Convertible notes, net of issuance costs

     275,581       257,789       (23,000     I        510,370  

Long-term debt

     94,321       48,470       2,028       J        144,819  

Other liabilities

     —         4,612       —            4,612  

Total liabilities

   $ 637,739     $ 572,050     $ 409,527        $ 1,619,316  

Stockholders’ equity

           

Common stock(1)

     1,601,853       16       26       B        42  
         (1,601,853     B     

Additional paid-in capital

     34,181       1,095,781       3,381,263       A, B        5,018,671  
         (1,095,781     B     
         1,390       I     
         1,601,837       B     

Warrants

     277       —         —            277  

Accumulated other comprehensive income

     (309     8,205       (8,205     B        (309

Accumulated deficit

     (243,969     (730,103     730,103       B        (296,480
         (33,841     K     
         (6,823     L     
         (11,847     M     

Total stockholders’ equity

     1,392,033       373,899       2,956,269          4,722,201  

Non-controlling interests

     50,383       —         —            50,383  

Total liabilities and stockholders’ equity

   $ 2,080,155     $ 945,949     $ 3,365,796        $ 6,391,900  

 

(1)

Consists of Aphria common shares and Tilray Class 2 common stock

 

2


Unaudited Pro Forma Condensed Combined Statement of Net Loss

For the Year Ended December 31, 2020

(in ‘000 of United States dollars, except per share and share amounts)

 

     Aphria constructed
12 month period

ending November 30,
2020 (note 6)
    Tilray 12 month
period ending
December 31, 2020
    Transaction
accounting
adjustments
    Notes
(note 4)
     Pro forma
combined
 

Revenue

   $ 471,963     $ 210,482     $ —          $ 682,445  

Cost of sales

     351,229       185,827       27,355       C        565,841  
         (56     D     
         1,486       L     

Gross profit

     120,734       24,655       (28,785        116,604  

General and administrative expenses

     112,069       85,883       33,841       K        231,117  
         6,823       L     
         (7,499     L     

Sales and marketing expenses

     45,719       54,666       (6,729     L        93,656  

Research and development expenses

     1,275       4,411       207       L        5,893  

Depreciation and amortization expenses

     15,123       13,722       (798     D        55,945  
         27,898       F     

Impairment of assets

     47,643       61,114       —            108,757  

Loss from equity method investments

     —         5,983       —            5,983  

Operating loss

     (101,095     (201,124     (82,528        (384,747

Foreign exchange loss (gain), net

     5,800       (13,169     —            (7,369

Change in fair value of warrant liability

     —         100,286       —            100,286  

Gain on debt conversion

     —         (61,118     —            (61,118

Interest expenses, net

     21,550       39,219       (5,258     I        55,185  
         (327     J     

Other expense (income), net

     83,044       10,333       —            93,377  

Loss before income taxes

     (211,489     (276,675     (76,943        (565,107

Deferred income tax recoveries

     (40,544     (5,376     (16,211     M        (58,889
         3,242       M     

Current income tax (recoveries) expenses

     18,592       (226     —            18,366  

Net loss

   $ (189,537   $ (271,073   $ (63,974      $ (524,584

Net loss per share - basic and diluted

     $ (2.05        $ (1.32

Weighted average shares used in computation of net loss per share - basic and diluted

       126,041,710       271,794,347       note 5        397,836,057  

 

3


NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

(in ‘000 of United States dollars, except for shares, warrants, per share amounts and per warrant amounts, unless otherwise noted)

 

1.

Basis of Presentation

The pro forma financial statements are based on the historical consolidated financial statements of Tilray and Aphria, adjusted to give effect to the merger transaction, and should be read in conjunction with the historical financial statements from which they are derived. Pro forma adjustments are limited to the transaction accounting adjustments that reflect the accounting for the merger transaction in accordance with US GAAP.

The pro forma financial statements were prepared using the purchase method of accounting. The merger transaction is accounted for as a reverse acquisition in which Tilray is the legal acquirer and Aphria is the acquirer for accounting purposes. Accordingly, the pro forma financial statements represent a continuation of the financial statements of Aphria; the assets and liabilities of Aphria are presented at their historical carrying values and the assets and liabilities of Tilray are recognized on the effective date of the merger transaction and measured at fair value.

The pro forma financial statements are presented in United States dollars (“USD”) and prepared in accordance with US GAAP. Since Aphria’s historical consolidated financial statements are presented in Canadian dollars (“CAD” or “C$”) and prepared in accordance with International Financial Reporting Standards (“IFRS”), the historical financial information of Aphria used in the pro forma financial statements has been reconciled to US GAAP and translated into USD (note 6).

The pro forma balance sheet gives effect to the merger transaction as if it had occurred on December 31, 2020. The pro forma statement of net loss gives effect to the merger transaction as if it had occurred on January 1, 2020.

The pro forma balance sheet combines the audited consolidated balance sheet of Tilray as at December 31, 2020 with the unaudited condensed consolidated statement of financial position (balance sheet) of Aphria as at November 30, 2020. As the ending date of the fiscal period for Aphria differs from that of Tilray by more than 93 days, the unaudited pro forma statement of operations (statement of net loss) for the year ended December 31, 2020 was derived by combining financial information from the audited consolidated statement of net loss and comprehensive loss of Tilray for the year ended December 31, 2020 with financial information of Aphria for the twelve months ended November 30, 2020, which was constructed by subtracting: (i) the financial information from the unaudited consolidated statement of operations for the six months ended November 30, 2019; from (ii) the financial information from the audited consolidated statement of operations for the year ended May 31, 2020; and adding (iii) the financial information from the unaudited consolidated statement of operations for the six months ended November 30, 2020 (note 6). The financial statements of Aphria used to prepare the pro forma balance sheet and the pro forma statements of operations (statement of net loss) were prepared for the purpose of such pro forma financial statements and do not conform with the financial statements for Aphria included, or incorporated by reference, elsewhere in the Circular. Tilray’s audited consolidated balance sheet as of December 31, 2020 and audited consolidated statement of net loss and comprehensive loss for the year ended December 31, 2020 are included Part II, Item 8 - Financial Statements and Supplementary Data, of Tilray’s Consolidated Financial Statements filed on Form 10-K with the SEC on February 19, 2021.

The assumptions and estimates underlying the adjustments to the pro forma financial statements are described in the accompanying notes.

The pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed. The pro forma adjustments have been made solely for the purpose of providing unaudited pro forma combined financial information and actual adjustment, when recorded, may differ materially.

The pro forma financial statements have been prepared for illustrative purposes only and may not be indicative of the operating results or financial condition that would have been achieved if the merger transaction had been completed on the dates or for the periods presented, nor do they purport to project the results of operations or financial position for any future period or as of any future date. In addition to the pro forma adjustments, various other factors will have an effect on the financial condition and results of operations after the completion of the merger transaction. The actual financial position and results of operations may differ materially from the pro forma amounts reflected herein due to a variety of factors.

The unaudited pro forma financial statements do not reflect operational and administrative cost savings that may be achieved as a result of the merger transaction.

 

4


2.

Estimated Purchase Price

Tilray is the legal acquirer and, pursuant to the Plan of Arrangement, will (i) exchange each outstanding Aphria common share for 0.8381 of a Tilray Class 2 common share (the “Exchange Ratio”), and (ii) exchange outstanding equity instruments exercisable into Aphria common shares for instruments with similar terms that are exercisable into Tilray Class 2 common shares, adjusted to reflect the Exchange Ratio.

However, since the merger transaction is being accounted for as a reverse acquisition (note 1), the purchase price is calculated as the fair value of the hypothetical consideration Aphria would have to issue to acquire Tilray’s outstanding equity instruments and obtain the same percentage of ownership interest in the combined entity that will result from the merger transaction.

The estimated purchase price of $3,381,289 is based on the number of equity instruments of Tilray outstanding at December 31, 2020, adjusted for the exercise of 6,290,000 warrants (note 3, 4H), and Aphria’s closing share price of $16.60 on February 3, 2021 (the “Measurement Date”). The purchase price will change based on fluctuations in Aphria’s share price and the number of equity instruments of Tilray outstanding on the effective date of the merger transaction. A 10% increase or decrease in Aphria’s share price would increase or decrease both the purchase price and goodwill by approximately $338,924, respectively, and a 25% increase or decrease in Aphria’s share price would increase or decrease both the purchase price and goodwill by approximately $847,299, respectively.

The following table summarizes the calculation of the purchase price hypothetically paid by Aphria (in thousands, except warrants, share and per share data):

 

Tilray Class 2 common stock outstanding at December 31, 2020 adjusted for warrants exercised(1)

     164,746,087  

Aphria common stock hypothetically issued based on Exchange Ratio

     196,570,919  

Price per common stock of Aphria on Measurement Date

   $ 16.60  

Total estimated fair value of acquired Tilray Class 2 common stock

   $ 3,263,077  

Estimated fair value of Tilray stock-based compensation related to the precombination service period

   $ 118,212  

Total estimated purchase price

   $ 3,381,289  

 

(1)

Represents 158,456,087 Tilray Class 2 common stock outstanding at December 31, 2020 and 6,290,000 warrants exercised from Jan 1, 2021 to the Measurement Date (note H)

The estimated fair value of the Tilray stock-based compensation related to the precombinaion service period consisted of $91,089 related to Tilray stock options and $27,123 related to restricted share units (“RSUs”). The fair values of the RSUs included in the purchase price are estimated using the market share price of Aphria on the purchase price Measurement Date. The fair values of the options included in the purchase price are calculated using the Black Scholes model, using the following assumptions:

 

Volatility

     100%  

Dividend yield

     0%  

Risk-free interest rate

     0.03% to 0.96%  

Expected term

     0.06 to 8.13 years  

 

3.

Preliminary Purchase Price Allocation

A preliminary valuation analysis of the fair value of Tilray’s assets and liabilities has been performed at December 31, 2020, with the following exception:

 

   

The warrant liability has been valued at the Measurement Date, which reflects the exercise of 6,290,000 warrants between January 1, 2021 and the Measurement Date (note 2, 4H); and

 

   

The cash and cash equivalents balance at December 31, 2020 has been increased by $37,426 (note 4H) to reflect the cash received upon exercise of the warrants.

 

5


The purchase price has been allocated to such assets and liabilities, with the excess allocated to goodwill. The following table summarizes the preliminary purchase price allocation:

 

Cash and cash equivalents

   $ 227,128  

Accounts receivable

     29,033  

Inventory

     121,000  

Prepayments and other current assets

     34,640  

Property and equipment

     201,049  

Operating right-of-use assets

     18,259  

Intangible assets

     1,063,000  

Equity method investments

     9,300  

Other investments

     14,369  

Other assets

     4,356  

Accounts payable

     (17,776

Accrued expenses and other current liabilities

     (39,946

Accrued lease obligations

     (33,536

Warrant liability

     (296,032

Deferred tax liability

     (251,877

Convertible notes

     (236,179

Long-term debt

     (50,498

Other liabilities

     (4,612

Goodwill

     2,589,611  

The preliminary purchase price allocation has been used to prepare the pro forma adjustments (note 4). The purchase price allocation will be finalized following the effective date of the merger transaction when the valuation analysis is complete. The final allocation could differ materially from the preliminary allocation used in the pro forma adjustments.

 

4.

Pro Forma Adjustments

Adjustments to the pro forma financial statements are limited to those that reflect the accounting for the merger transaction in accordance with US GAAP. The pro forma financial statements give effect to the merger transaction as if it had occurred on December 31, 2020 for purposes of the pro forma balance sheet and January 1, 2020 for purposes of the pro forma statement of net loss.

The pro forma adjustments are as follows:

A – Purchase price

Records the purchase price consideration, which is the fair value of the equity interests hypothetically issued by Aphria to acquire Tilray (note 2).

 

6


B – Equity

Eliminates Tilray’s historical equity balances and reallocates Aprhia’s equity balances so the equity structure appearing in the pro forma balance sheet reflects the legal equity structure of Tilray, including the equity interests issued by Tilray to effect the merger transaction.

The following table summarizes how the equity balances in the pro forma balance sheet were determined:

 

     Common stock     Additional
paid-in capital
    Warrants      Accumulated other
comprehensive
income
    Accumulated
deficit
    Total  

Aphria as at November 30, 2020

   $ 1,601,853     $ 34,181     $ 277      $ (309   $ (243,969   $ 1,392,033  

Total estimated purchase price (note 2, 4A)

     26       3,381,263       —          —         —         3,381,289  

Tilray as at December 31, 2020

     16       1,095,781       —          8,205       (730,103     373,899  

Eliminate Tilray as at December 31, 2020

     —         (1,095,781     —          (8,205     730,103       (373,883

Reallocate balance to reflect Tilray structure

     (1,601,853     1,601,837          —         —         (16

Equity component of Tilray convertible notes (note 4I)

     —         1,390       —          —         —         1,390  

Accumulated deficit impact of pro forma adjustments (note 4K, 4L, 4M)

     —         —         —          —         (52,511     (52,511

Pro forma - December 31, 2020

   $ 42     $ 5,018,671     $ 277      $ (309   $ (296,480   $ 4,722,201  

The $26 pro forma balance as part of the total estimated purchase price represents the $0.0001 par value of the estimated 265,504,347 of Tilray Class 2 common stock issued on the merger transaction.

C – Inventory

Increases Tilray’s inventory to a fair value of approximately $121,000, an increase of $27,355 from the carrying value. The fair value was determined based on the estimated selling price of the inventory, less the remaining manufacturing and selling costs and a normal profit margin on those manufacturing and selling efforts. After the merger transaction, the $27,355 step-up in inventory value will increase cost of sales over the following twelve months as the inventory is sold, which is reflected in the pro forma statement of net loss and represents a nonrecurring charge. The fair value calculation is preliminary and subject to change.

D – Property and equipment

Increases Tilray’s property and equipment to an estimated fair value of approximately $201,049, an overall increase of $1,490 from the carrying value. The overall increase represents an estimated increase of $2,110 relating to finance lease right-of-use assets (note 4E) offset by an estimated decrease of $620 to property and equipment. The estimated useful lives, excluding land, range from 4 to 27 years. The estimated fair value of property and equipment, excluding finance lease right-of-use assets is determined primarily using an income approach, which requires a forecast of expected future cash flows. After the merger transaction, the estimated impact of the combined change in the value and useful lives of property and equipment will be an estimated decrease in depreciation expense in the pro forma statement of net loss recognized through a $56 decrease in cost of sales and $798 decrease in depreciation and amortization expense. The estimated fair value and estimated useful life calculations are preliminary and subject to change.

 

7


The following table summarizes the changes in the estimated depreciation expense for property and equipment including finance lease right-of-use assets in the pro forma statement of net loss based on a straight-line method of depreciation:

 

Estimated annual depreciation expense:

  

Included in cost of sales

   $ 4,876  

Included in depreciation and amortization expenses

     1,922  

Historical depreciation expense:

  

Included in cost of sales

     4,932  

Included in depreciation and amortization expenses

     2,720  

Pro forma decrease to depreciation expense:

  

Decrease included in cost of sales

     (56

Decrease included in depreciation and amortization expenses

     (798

The preliminary estimates of fair value and estimated useful lives will likely differ from the final amounts after completing a detailed valuation analysis, and the difference could have a material effect on the accompanying pro forma financial statements. A 10% change in the estimated fair value of property and equipment, excluding finance lease right-of-use assets, would cause a corresponding increase or decrease in the balance of goodwill. A 10% change would also cause the annual depreciation expense in the pro forma statement of net loss to increase or decrease by approximately $646, assuming a weighted average useful life of depreciable property and equipment of 18.4 years.

E – Leases

Included in Tilray’s property and equipment carrying value (note 4D) is $13,167 related to finance lease right-of-use assets. The carrying value has been adjusted to the corresponding carrying value of finance lease liabilities of $15,277, resulting in a pro forma increase of $2,110. The corresponding impact to depreciation expense is included in property and equipment (note 4D). The carrying value of Tilray’s operating lease right-of-use assets has been adjusted to the corresponding carrying value of operating lease liabilities of $18,259, resulting in a pro forma increase of $274. The finance and operating lease liabilities, and corresponding right-of-use assets may differ from the final amounts after completing the detailed incremental borrowing rate analysis.

F – Intangible assets

Increases Tilray’s intangible assets to an estimated fair value of approximately $1,063,000, an increase of $876,555 from the carrying value. As part of the preliminary valuation analysis, the identified intangible assets include distribution channels, customer relationships, know how, developed technology, licenses, brands and trademarks. The fair value of identifiable intangible assets is determined primarily using an income approach, which requires a forecast of expected future cash flows. For purposes of the preliminary fair value, the mid point of the estimated range has been used. After the merger transaction, the $876,555 increase in the value of intangible assets will increase amortization expense over the respective estimated useful lives, which is reflected in the pro forma income statement through a $27,898 increase in depreciation and amortization expenses.

The following table summarizes the estimated fair values (mid point) of Tilray’s identifiable intangible assets and, where applicable, their estimated useful lives:

 

     Estimated fair value      Estimated useful life
(years)
 

Definite-lived intangible assets

     

Distribution channels

   $ 137,000        15  

Customer relationships

     85,000        15  

Know how

     47,000        2  

Developed technology

     6,000        10  
     275,000     

Indefinite-lived intangible assets

     

Licenses

     660,000        Indefinite  

Brands

     116,000        Indefinite  

Trademarks

     12,000        Indefinite  
     788,000     
   $ 1,063,000     

 

8


The following table summarizes the changes in the estimated amortization expense recorded to depreciation and amortization expense in the pro forma statement of net loss based on a straight-line method of amortization:

 

Estimated annual amortization expense

   $ 38,900  

Historical amortization expense

     11,002  

Pro forma increase to amortization expense

   $ 27,898  

The preliminary estimates of fair value and estimated useful lives will likely differ from the final amounts after completing a detailed valuation analysis, and the difference could have a material effect on the accompanying pro forma financial statements. A 10% change in the estimated fair value of intangible assets would cause a corresponding increase or decrease in the balance of goodwill. A 10% change would also cause the annual amortization expense in the pro forma statement of net loss to increase or decrease by approximately $3,890, assuming an overall weighted average useful life of definite-lived intangible assets of 12.7 years.

G – Goodwill

Adjusts goodwill in the pro forma balance sheet as follows:

 

Reversal of Tilray’s historical goodwill

   $ (166,915

Goodwill recognized in purchase accounting

     2,589,611  

Pro forma increase to goodwill

   $ 2,422,696  

H – Warrant liability

Increases Tilray’s warrant liability to an estimated fair value of approximately $296,032, an increase of $175,385 from the carrying value to reflect the estimated fair value at the Measurement Date. The 19,000,000 outstanding warrants at December 31, 2020 are reduced for the additional exercise of 6,290,000 warrants at a price of $5.95 from January 1, 2021 to the Measurement Date. The resulting increase in cash on exercise of $37,426 is an adjustment to the carrying value of cash in the purchase price allocation. The remaining 12,710,000 warrants outstanding on the Measurement Date have an estimated fair value of $23.29 per warrant, using Tilray’s market share price on the Measurement Date as an input.

I – Convertible notes

Adjusts the carrying value of the liability component of the convertible notes from $257,789 in Tilray’s historical balance sheet to an estimated fair value of $234,789, a decrease of $23,000. The fair value is determined using the expected cash flows, discounted by the estimated interest rate of similar nonconvertible debt based on current market rates. The combined instrument’s fair value of $236,179 is adjusted to present the equity component of $1,390 in equity (note 4B), with the remaining $234,789 recorded as a liability. The equity component is not remeasured as long as it continues to meet the conditions for equity classification. The adjusted debt discount is to be amortized as additional non-cash interest expense over the remaining term of the convertible notes using the interest method with an effective rate of 11.7 % per annum.

 

9


The following table summarizes the changes in the estimated interest expense related to convertible notes:

 

     Historical annual
interest expense
     Estimated annual
interest expense
     Pro Forma
(decrease)
increase to
interest
expense
 

Contractual coupon interest

   $ 22,929      $ 13,893      $ (9,036

Amortization of discount

     7,863        14,095        6,232  

Amortization of transaction costs

     2,454        —          (2,454

Total interest expense related to convertible notes

   $ 33,246      $ 27,988      $ (5,258

J – Long-term debt

Adjusts the carrying value of Tilray’s Senior Facility from $48,478 in Tilray’s historical balance sheet to $50,498, an increase of $2,028. The adjustment reflects removal of the unamortized transaction costs which are not recognized in a business combination.

The following table summarizes the changes in the estimated interest expense related to the Senior Facility:

 

     Historical annual
interest expense
     Estimated annual
interest expense
     Pro forma
increase
(decrease) in
interest expense
 

Contractual interest at Canadian prime plus 8.05%

   $ 4,257      $ 5,302      $ 1,045  

Amortization of transaction costs

     1,372        —          (1,372

Total interest expense related to Senior Facility

   $ 5,629      $ 5,302      $ (327

K – Transaction costs

Recognizes in both the pro forma balance sheet and pro forma statement of net loss $33,841 of nonrecurring transaction costs directly related to the merger transaction that are expected to be incurred by Aphria and Tilray subsequent to November 30, 2020 and December 31, 2020, respectively.

The following table summarizes the nonrecurring transaction costs related to the merger transaction included in general and administrative expenses in the pro forma statement of net loss:

 

     Aphria      Tilray      Total  

Expensed in historical financial statements

   $ 955      $ 2,232      $ 3,187  

Accrued in pro forma adjustment

     23,212        10,629        33,841  

Total recognized in pro forma statement of net loss

   $ 24,167      $ 12,861      $ 37,028  

L – Compensation arrangements

Recognizes in both the pro forma balance sheet and pro forma income statement $6,823 of nonrecurring compensation costs related to severance payments and retention payments. This pro forma adjustment excludes any related severance or other compensation costs which may be triggered upon an announcement of a new executive team or other headcount restructuring that may result from the merger transaction.

The following table summarizes the nonrecurring compensation costs related to the merger transaction included in the pro forma income statement:

 

     Aphria      Tilray      Total  

Expensed in historical financial statements

   $ —        $ —        $ —    

Accrued in pro forma adjustment

     —          6,823        6,823  

Total recognized in pro forma statement of net loss

   $ —        $ 6,823      $ 6,823  

 

10


Also recognizes in the pro forma statement of net loss is compensation costs related to the difference between Tilray’s historical share-based compensation expense and the estimated share-based compensation expense related to replacement stock options and restricted stock units hypothetically issued by Aphria as consideration. The portion of the fair value of the replacement share-based awards related to compensation costs will be recognized ratably over post-merger service periods ranging from 0 to 3 years. The following table summarizes the changes in the estimated Tilray stock-based compensation expense in the pro forma statement of net loss:

 

     Historical
stock-based
compensation
expense
     Estimated
annual stock-
based

compensation
expense
     Pro forma
increase
(decrease) in
stock-based
compensation
expense
 

Cost of sales

   $ 1,568      $ 3,054      $ 1,486  

General and administration expenses

     20,491        12,993        (7,499

Sales and marketing

     6,729        —          (6,729

Research and development expenses

     922        1,129        207  

Total stock-based compensation expense

   $ 29,710      $ 17,176      $ (12,535

The total pro forma adjustment to stock-based compensation expense excludes the impact of accelerated vesting of Aphria’s stock-based awards that is subject to the approval by the Aphria Board, which has not yet occurred.

M – Income taxes

The pro forma income tax adjustments to the pro forma balance sheet results in an overall increase in the deferred income tax liability of $214,450 relating to the following:

 

   

Increase of $202,603 related to Tilray’s increase in taxable temporary differences due primarily to fair value increases in inventory, property and equipment, and intangibles, offset by a partial reversal of the valuation allowance on net operating losses carrying forward in several legal entities and jurisdictions; and

 

   

Increase of $11,847 related to restrictions on Aphria’s losses in several legal entities and jurisdictions, and valuation allowances due to the impact of the merger transaction.

The pro forma income tax adjustments to the pro forma statement of net loss are comprised of the following amounts:

 

(a)

Tax impact of pro forma adjustments:

 

Tax impact of pro forma adjustments    Increase
(decrease)
     Deferred tax
expense
(recovery)
 

C - Inventory (cost of sales)

   $ 27,355      $ (2,227

D - Property and equipment (depreciation expense)

     (854      226  

F - Intangible assets (amortization expense)

     27,898        (7,532

I - Convertible debt (interest expense)

     (5,258      —    

J - Long-term debt (interest expense)

     (327      —    

K - Transaction costs

     33,841        —    

L - Compensation

     (5,712      —    
     76,944        (9,533

M - Income taxes—benefit of current year losses

     —          (6,678
   $ 76,944      $ (16,211

 

11


The $16,211 deferred tax recovery is comprised of the following:

 

   

$9,533 which relates to the tax-effect of pro-forma adjustments, C, D, F. The remaining pro-forma statement of loss adjustments are not tax-effected due to the amounts being non-deductible for tax purposes, or the benefit of the deductible expense cannot be recognized due to a valuation allowance in the legal entity and jurisdiction to which it relates; and

 

   

$6,678 which relates to the deferred tax asset that can be recognized for a portion of the current period loss.

 

(b)

Reversal of $3,242 of deferred tax recoveries recorded by Aphria during the twelve months ended November 30, 2020 which would either not be eligible for recovery or require a valuation allowance as a result of the merger transaction.

 

5.

Pro Forma Loss Per Share

 

Historical Tilray basic weighted average shares at December 31, 2020

     126,041,710  

Adjustment for warrants exercised at Measurement Date (note 3, note 4H)

     6,290,000  

Incremental shares issued in merger transaction (note 4B)

     265,504,347  

Pro forma combined basic and diluted weighted average shares

     397,836,057  

On a pro forma basis, the combined company incurred a net loss for the year ended December 31, 2020. As such, all potential shares are excluded from the calculation of pro forma diluted loss per share because they are anti-dilutive.

 

6.

Adjustments to the Historical Financial Information of Aphria

The historical financial information of Aphria was prepared in accordance with IFRS as issued by the IASB and presented in CAD. Aphria’s fiscal year end is May 31 and historical financial information was used to present pro forma financial statements based on the fiscal year of Tilray being December 31. Reclassification adjustments have been made to Aphria’s historical financial information to comply with Tilray’s presentation which resulted in a net impact of $nil on the net loss for the period presented and on the adjusted unaudited condensed consolidated statement of financial position of Aphria.

The historical financial information was translated from CAD to USD using the following historical exchange rates:

 

     CAD to USD  

Period end exchange rate as at November 30, 2020

     0.7698  

Average exchange rate for the year ended November 30, 2020

     0.7439  

Average exchange rate for the six months ended November 30, 2020

     0.7516  

Average exchange rate for year ended May 31, 2020

     0.7460  

Average exchange rate for the six months ended November 30, 2019

     0.7561  

 

12


The table below presents the conversion from IFRS to US GAAP adjustments as well as the presentation and reclassification adjustment which had a $nil impact on the total assets, liabilities and deficit accounts and translation of Aphria’s adjusted unaudited condensed consolidated statement of financial position as at November 30, 2020:

Adjusted Unaudited Condensed Consolidated Statement of Financial Position (Balance Sheet) of Aphria

(in ‘000)

 

     IFRS                  US GAAP  
     As at November
30, 2020

CAD
    IFRS to US
GAAP
differences
CAD
    Notes
(note 6)
     As at November 30,
2020
CAD
    Presentation
reclassification
CAD
    Adjusted
presentation
CAD
    Adjusted
presentation
USD
 

Assets

               

Current assets:

               

Cash and cash equivalents

   $ 187,997     $ —          $ 187,997     $ —       $ 187,997     $ 144,713  

Accounts receivable, net

     96,177       —            96,177       —         96,177       74,034  

Inventory

     321,484       (112,442     i        209,042       18,063       227,105       174,817  

Biological assets

     28,952       (10,889     i        18,063       (18,063     —         —    

Prepayments and other current assets

     48,162       15,704       vi        63,866       9,371       73,237       56,375  

Current portion of convertible notes receivable

     9,371       —            9,371       (9,371     —         —    

Total current assets

     692,143       (107,627        584,516       —         584,516       449,939  

Property and equipment, net

     655,114       (6,650     iii        648,464       —         648,464       499,164  

Operating lease, right-of-use assets

     —         7,006       iii        7,006       —         7,006       5,393  

Intangible assets, net

     686,440       —            686,440       —         686,440       528,397  

Goodwill

     752,289       (1,200     vii        751,089       —         751,089       578,161  

Other investments

     21,815       —            21,815       —         21,815       16,792  

Other assets

     —         —            —         3,000       3,000       2,309  

Promissory notes receivable

     3,000       —            3,000       (3,000     —         —    

Total assets

   $ 2,810,801     $ (108,471      $ 2,702,330     $ —       $ 2,702,330     $ 2,080,155  

Liabilities

               

Current liabilities

               

Bank indebtedness

     5,111       —            5,111       —         5,111       3,934  

Accounts payable

     —         —            —         81,411       81,411       62,667  

Accrued expenses and other current liabilities

     —         —            —         152,646       152,646       117,501  

Accounts payable and accrued liabilities

     254,318       (20,261     ii        234,057       (234,057     —         —    

Income taxes payable

     16,576       —            16,576       —         16,576       12,760  

Accrued lease obligations

     1,767       —            1,767       —         1,767       1,360  

Current portion of long-term debt

     15,210       —            15,210       —         15,210       11,708  

Total current liabilities

     292,982       (20,261        272,721       —         272,721       209,930  

Accrued lease obligations

     44,896       —            44,896       —         44,896       34,560  

Deferred tax liability

     45,391       (15,061     vi        30,330       —         30,330       23,347  

Long-term debt

     122,533       —            122,533       —         122,533       94,321  

Convertible notes, net of issuance costs

     358,008       —            358,008       —         358,008       275,581  

Total liabilities

   $ 863,810     $ (35,322      $ 828,488     $ —       $ 828,488     $ 637,739  

Shareholders’ equity

               

Share capital

     2,078,343       2,624       ii        2,080,967       (2,080,967     —         —    

Common stock

     —         —            —         2,080,967       2,080,967       1,601,853  

Additional paid-in capital

     —         —            —         44,404       44,404       34,181  

Warrants

     360       —            360       —         360       277  

Share-based payment reserve

     29,600       14,804       ii        44,404       (44,404     —         —    

Accumulated other comprehensive income

     —         —            —         (402     (402     (309

Accumulated other comprehensive loss

     (211     (191     v        (402     402       —         —    

Accumulated deficit

     (215,739     (92,472     i        (316,940     —         (316,940     (243,969
       2,833       ii           
       262       iii           
       (10,815     iv           
       191       v           
       (1,200     vii           

Total stockholders’ equity

   $ 1,892,353     $ (83,964      $ 1,808,389     $ —       $ 1,808,389     $ 1,392,033  

Non-controlling interests

     54,638       10,815       iv        65,453       —         65,453       50,383  
     1,946,991       (73,149        1,873,842       —         1,873,842       1,442,416  

Total liabilities and stockholders’ equity

   $ 2,810,801     $ (108,471      $ 2,702,330     $ —       $ 2,702,330     $ 2,080,155  

 

13


Adjusted Unaudited Condensed Consolidated Statement of Operations (Statement of Loss) of Aphria

(in ‘000)

 

     IFRS                  US GAAP  
     Year ended
May 31,
2020
CAD
    6 months
ended
November 30,
2019
CAD
    6 months
ended
November 30,
2020
CAD
    12 months
ended
November 30,
2020
CAD
    IFRS to
US

GAAP
differences
CAD
    Notes
(note 6)
     12 months
ended
November 30,
2020
CAD
    Presentation
reclassification
CAD
    12 months
ended
November 30,
2020
CAD
    12 months
ended
November 30,
2020
USD
 

Revenue

   $ —       $ —       $ —       $ —       $ —          $ —       $ 634,459     $ 634,459     $ 471,963  

Cannabis revenue

     204,736       —         —         204,736       —            204,736       (204,736     —         —    

Distribution revenue

     369,214       —         —         369,214       —            369,214       (369,214     —         —    

Insurance recovery

     1,000       —         —         1,000       —            1,000       (1,000     —         —    

Excise taxes

     (31,611     —         —         (31,611     —            (31,611     31,611       —         —    

Net revenue

     —         246,712       306,221       59,509       —            59,509       (59,509     —         —    

Cost of sales

     —         —         —         —         —            —         472,157       472,157       351,229  

Production costs

     64,972       —         —         64,972       500       i        65,472       (65,472     —         —    

Cost of cannabis purchased

     21,920       —         —         21,920       —            21,920       (21,920     —         —    

Cost of goods purchased

     322,688       —         —         322,688       —            322,688       (322,688     —         —    

Cost of goods sold

     —         188,670       219,136       30,466       —            30,466       (30,466     —         —    

Fair value adjustment on sale of inventory

     57,039       19,677       57,556       94,918       (94,918     i        —         —         —         —    

Fair value adjustment on growth of biological assets

     (115,255     (46,645     (85,242     (153,852     153,852       i        —         —         —         —    

Gross profit

     191,975       85,010       114,771       221,736       (59,434        162,302       —         162,302       120,734  

General and administrative expenses

     99,977       44,381       56,144       111,740       1,667       iii        113,407       37,248       150,655       112,069  

Sales and marketing expenses

     —         —         —         —         —            —         61,460       61,460       45,719  

Selling

     21,042       7,642       14,751       28,151       —            28,151       (28,151     —         —    

Marketing and promotion

     20,464       12,426       11,380       19,418       —            19,418       (19,418     —         —    

Research and development expenses

     2,568       1,282       428       1,714       —            1,714       —         1,714       1,275  

Stock-based compensation

     22,500       12,519       17,856       27,837       (6,659     ii        21,178       (21,178     —         —    

Depreciation and amortization expenses

     21,747       10,904       11,056       21,899       (1,569     iii        20,330       —         20,330       15,123  

Impairment of assets

     63,971       —         —         63,971       75       iii        64,046       —         64,046       47,643  

Acquisition-related expenses, net

     5,763       1,426       25,624       29,961       —            29,961       (29,961    

Operating loss

     (66,057     (5,570     (22,468     (82,955     (52,948        (135,903     —         (135,903     (101,095

Foreign exchange loss (gain), net

     —         —         —         —         —            —         7,797       7,797       5,800  

Interest expense, net

     26,347       10,263       13,277       29,361       (391     iii        28,970       —         28,970       21,550  

Other expense (income), net

     —         —         —         —         —            —         111,636       111,636       83,044  

Non-operating (income) expense, net

     (11,687     (24,871     107,119       120,303       (870     v        119,433       (119,433     —         —    

Loss before income taxes

     (80,717     9,038       (142,864     (232,619     (51,687        (284,306     —         (284,306     (211,489

Deferred income tax recoveries

     —         —         —         —         (15,788     vi        (15,788     (38,715     (54,503     (40,544

Current income tax expenses

     —         —         —         —         —            —         24,993       24,993       18,592  

Income taxes expense (recoveries)

     3,917       526       (17,171     (13,780     58       vi        (13,722     13,722       —         —    

Net loss

   $ (84,634   $ 8,512     $ (125,693   $ (218,839   $ (35,957      $ (254,796   $ —       $ (254,796   $ (189,537

 

14


IFRS differs in certain material respects from US GAAP. The following material adjustments have been made to reflect Aphria’s historical consolidated statement of loss on a US GAAP basis for purposes of the unaudited pro forma financial information (expressed in thousands of CAD), these adjustments are before certain reclassification adjustments:

i – Inventory and biological assets

Cannabis plants are accounted for as biological assets and agricultural products under IFRS and US GAAP, respectively. Under IFRS, biological assets are accounted for at fair value less costs to sell and are revalued at each subsequent reporting date up to the point of harvest, upon which time they are transferred into inventories. Any change in fair value is recognized in the period of change within profit or loss. Under US GAAP, agricultural products are accounted for at cost in accordance with guidance on property, plant and equipment or inventories depending on their nature.

The following table reflects the removal of the fair value adjustment that was included in the cost basis of inventories and biological assets under IFRS to reflect cannabis plants at cost in accordance with Accounting Standards Codification 330, Inventory as required under US GAAP and includes a corresponding impact to accumulated deficit:

 

     As at November 30,
2020
CAD
 

Inventory

   $ (112,442

Biological assets

     (10,889

Accumulated deficit, net of tax of $30,859

     (92,472

The following table reflects the removal of the changes in fair value recognized in the period of change within the statement of operations:

 

     Year ended
May 31, 2020
CAD
     6 months ended
November 30, 2019
CAD
     6 months ended
November 30, 2020
CAD
     12 months ended
November 30, 2020
CAD
 

Production costs

   $ 5,000      $ 4,500      $ —        $ 500  

Fair value adjustment on sale of inventory

     (57,039      (19,677      (57,556      (94,918

Fair value adjustment on growth of biological assets

     115,255        46,645        85,242        153,852  

 

15


ii – Share-based payments

Under US GAAP, Restricted Stock Units (“RSUs”) and Deferred Stock Units (“DSUs”) that can be settled in either cash or equity at the option of Aphria should be classified as equity. Currently, Aphria classifies its RSUs and DSUs as liabilities. Under US GAAP, Aphria measures and recognizes compensation expense for these awards on a straight-line basis over the requisite service period for each separately vesting portion of the award as if the award was, in substance, multiple awards based on their grant date fair value.

The following table reflects the removal of the RSU and DSU liability in accounts payable and accrued liabilities and the reclassification of the awards to equity:

 

     As at November 30,
2020
CAD
 

Accounts payable and accrued liabilities

   $ (20,261

Share capital

     2,624  

Share-based payment reserve

     14,804  

Accumulated deficit

     2,833  

This adjustment also reflects the impact to share-based compensation of C$1,735 for the year ended May 31, 2020; C$879 for the six months ended November 30, 2019; (C$7,515) for the six months ended November 30, 2020, for a total adjustment of (C$6,659) for the twelve months ended November 30, 2020.

iii – Leases

Under US GAAP, at lease commencement, a lessee classifies a lease as a finance lease or an operating lease (unless the short-term lease recognition exemption is elected). Under IFRS, lessees do not classify leases and all leases are treated under a single model (unless the short-term leases or leases of low-value asset recognition exemptions are elected). For operating leases under US GAAP, the subsequent measurement of the lease liability is based on the present value of the remaining lease payments using the discount rate determined at lease commencement (which would result in the same amount of lease liability as in IFRS), while the right-of-use asset is remeasured at the amount of the lease liability, adjusted for the remaining balance of any lease incentives received, cumulative prepaid or accrued rents, unamortized initial direct costs and any impairment. This treatment under US GAAP generally results in straight-line expense being incurred over the lease term and recorded to general and administrative expenses. IFRS generally yields front-loaded expense recognition. Under IFRS, a constant interest rate is applied to the lease liability, interest expense decreases as cash payments are made during the lease term and the lease liability decreases. Therefore, more interest expense is incurred in the early periods and less in the later periods. This trend in the interest expense, combined with straight-line depreciation of the right-of-use asset, results in a front-loaded expense recognition pattern.

The following table reflects the adjustments to the right-of-use asset for operating leases under US GAAP, the corresponding impact to accumulated deficit and reclassifies the right-of-use asset from property and equipment, net to operating lease, right-of-use assets:

 

     As at November 30,
2020
CAD
 

Operating lease, right-of-use assets

   $ 7,006  

Property and equipment, net

     (6,650

Accumulated deficit, net of tax of $94

     262  

For the operating leases under US GAAP, the following table reflects the removal of amortization and interest expense recognized under IFRS and instead includes the straight-line operating lease expense as calculated under US GAAP in general and administrative expenses. Furthermore, additional impairment was recognized for the year ended May 31, 2020 under US GAAP for leases that were fully impaired under IFRS as a result of the adjustments to the associated right-of-use assets:

 

     Year ended
May 31, 2020
CAD
     6 months ended
November 30, 2019
CAD
     6 months ended
November 30, 2020
CAD
     12 months ended
November 30, 2020
CAD
 

General and administrative expenses

   $ 1,512      $ 630      $ 785      $ 1,667  

Depreciation and amortization expenses

     (1,455      (606      (720      (1,569

Impairment of assets

     75                      75  

Interest expense, net

     (380      (161      (172      (391

 

16


iv – Non-controlling interest on acquisition

Under US GAAP, non-controlling interest is measured at fair value on acquisition date. Under IFRS, Aphria measures non-controlling interest at the proportionate share of the fair value of the acquiree’s net identifiable assets and goodwill recorded on consolidation by Aphria would only reflect the acquirer’s share. This approach does not exist under US GAAP and the adjustment reflects the increase in non-controlling interests and accumulated deficit of C$10,815 as of November 30, 2020.

v – Investments in debt securities

US GAAP requires the use of three categories for the classification and measurement of debt securities based on the entity’s investment intent: held-to-maturity (“HTM”) - measured at amortized cost, trading - measured at fair value through profit or loss (“FVTPL”), available-for-sale (“AFS”) - measured at fair value through other comprehensive income (“FVOCI”). Under US GAAP, Aphria will classify its investments in debt securities as available-for-sale, measured at FVOCI. Since amounts were previously recognized at FVTPL under IFRS, this will result in a presentation reclassification difference.

This adjustment reflects the reversal of gains and losses recorded by Aphria for its investments in debt securities from non-operating income (expense), net into other comprehensive income of (C$7,341) for the year ended May 31, 2020; (C$6,939) for the six months ended November 30, 2019; (C$468) for the six months ended November 30, 2020, for a total adjustment of (C$870) for the twelve months ended November 30, 2020. This also results in a reclassification of amounts recognized in accumulated deficit to accumulated other comprehensive loss of C$191 as of November 30, 2020.

vi – Income taxes

For the purposes of the IFRS to US GAAP adjustments Aphria’s effective income tax rate was 26.5% for the year ended May 31, 2020, for the six months ended November 30, 2020 and for the six months ended November 30, 2019. The effective income tax rate was used in determining adjustments to:

 

   

Deferred tax liability of (C$15,061) as of November 30, 2020 as a result of the removal of the fair value adjustment of (C$30,859) from biological assets and inventory offset by an increase to the right-of-use asset under US GAAP C$94 and a reclassification of income taxes on intercompany transfers of inventory of C$15,704 that remain within the consolidated group from Deferred tax liability to Prepayments and other current assets. Under US GAAP, income tax expense paid by the transferor on intercompany profits from the transfer or sale of inventory within a consolidated group are deferred on consolidation, resulting in the recognition of a prepaid asset for the taxes paid rather than deferred taxes as required under IFRS.

 

   

Deferred income tax recoveries of C$15,179 for the year ended May 31, 2020; C$7,070 for the six months ended November 30, 2019; C$7,679 for the six months ended November 30, 2020, for a total adjustment of C$15,788 for the twelve months ended November 30, 2020 as a result of the removal of the fair value adjustments from biological assets and inventory under US GAAP.

 

   

Income taxes of C$66 for the year ended May 31, 2020; C$36 for the six months ended November 30, 2019; C$28 for the six months ended November 30, 2020, for a total adjustment of C$58 for the twelve months ended November 30, 2020 as a result of decreases to operating lease expense under US GAAP.

vii – Cannway Pharmaceuticals Inc.

In the fiscal year ending May 31, 2016, Aphria acquired 100% of the issued and outstanding shares of Cannway Pharmaceuticals Inc. Under IFRS, Aphria treated this transaction as a business combination and accordingly recorded goodwill of C$1,200. Under US GAAP, the transaction did not meet the definition of a business and is considered an asset acquisition. This adjustment reflects the removal of goodwill and includes a corresponding impact to accumulated deficit as the asset is fully amortized as of November 30, 2020.

 

17